NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Opko Health, Inc. OPK
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$606.9M
▼ 14.9% vs FY2024
EPS · FY25
$-0.30
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-17.1%
Net margin · FY25
-37.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 606.9M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 37 cents on every revenue dollar this year.
Per share
USD -0.30
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-17.1%
Return on equity, FY2025
ROE
Operating margin-19.3%
Net margin-37.2%
Return on assets-10.9%
Each USD of equity lost 17 cents this year.
Returned to shareholders
USD 47.0M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 47.0M
Share of profit-20.8%
Consecutive raises—
USD 47.0M in buybacks went back to shareholders in a year without profit.
Growth
−15.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−15.5%
−15.8%
+2.1%
+22.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.9B
total assets, end of FY2025
Total assetsUSD 1.9B
EquityUSD 1.3B
CashUSD 364.4M
Gross debtUSD 346.2M
Net debtUSD -18.2M
Current ratio3.97×
The company holds more cash than debt.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.6
0.7
0.9
1.0
1.8
1.4
0.9
1.0
1.0
1.1
0.5
0.1
0.1
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.2
−0.2
−0.2
0.0
0.1
−0.3
−0.2
−0.3
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.1
−0.1
−0.1
0.1
0.1
−0.2
−0.1
−0.2
0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
Income tax $B
−0.0
0.0
0.0
−0.1
0.0
0.0
0.0
−0.0
0.0
−0.1
−0.1
0.0
0.0
−0.0
−0.0
−0.0
−0.0
Net income $B
−0.2
−0.1
−0.2
−0.3
−0.0
0.0
−0.3
−0.2
−0.3
−0.0
−0.0
−0.2
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.30
−0.08
−0.25
−0.46
−0.05
0.05
−0.53
−0.27
−0.55
−0.10
−0.06
−0.41
−0.32
−0.11
−0.01
−0.08
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−17.1
−3.9
−12.8
−20.2
−1.8
1.9
−18.5
−8.4
−15.7
−2.4
−2.1
−20.0
−21.7
−17.1
−1.4
−69.3
−95.3
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
0.30
0.30
0.26
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
55 of 55
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed